Clinical and demographic characteristics of patients with chronic hepatitis Delta infection according to severity of liver disease by transient elastography.

<p>Clinical and demographic characteristics of patients with chronic hepatitis Delta infection according to severity of liver disease by transient elastography.</p

Linear correlation between liver and spleen features.

<p>Linear correlation (Sperman's rho, p value) between spleen and liver stiffness measurement (A) and between splenic volume and liver stiffness measurement (B).</p

Observed (unweighted, black) and weighted (IPCW-weighted, gray) annual CD4+ cell counts (median and interquartile range) since start of ART.

<p>Dashed lines represent important CD4+ cell count thresholds of 200, 350, and 500 cells/μL.</p

Unstratified and stratified observed and weighted median (interquartile range) CD4+ cell counts for years 1, 4, 7 and 10 after start of antiretroviral therapy and the percentage of patients with weighted CD4+ cell count >500/μL at year 10.

<p>HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.</p>a<p>Age at the start of ART.</p>b<p>Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU.</p>c<p>Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.</p>d<p>Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.</p>e<p>ADI at the start of ART was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART.</p>f<p>Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.</p

Risk factors associated with unreliability of spleen stiffness by the M probe (SSM-M).

<p>Risk factors associated with unreliability of spleen stiffness by the M probe (SSM-M).</p

Flow-chart.

<p>Study flow chart of patient's recruitment.</p

Demographic and clinical characteristics stratified by smoking status, HIV-infected individuals under care at IPEC, 2011–13.

<p>*Chi-square,</p><p>**Fischer exact test,</p><p>***Kruskal-Wallis.</p><p>Demographic and clinical characteristics stratified by smoking status, HIV-infected individuals under care at IPEC, 2011–13.</p

Diagnostic accuracy of spleen stiffness measurement and splenic volume.

<p>Area under the receiver operating characteristic (AUROC) curve for spleen stiffness measurement (A) and splenic volume (B) for prediction of compensated advanced chronic liver disease (c-ACLD) by transient elastography.</p

Univariate and multivariate analysis for factors associated with compensated Advanced Chronic Liver Disease (c-ACLD) based on liver stiffness measurement by transient elastography.

<p>Univariate and multivariate analysis for factors associated with compensated Advanced Chronic Liver Disease (c-ACLD) based on liver stiffness measurement by transient elastography.</p

Column 2: Demographic, behavioral and clinical characteristics of the study population (number [percentages] are given unless otherwise stated); Columns 3 to 8: Results of the logistic regression models for the three outcomes: ART discontinuation, Loss to Follow-up and Initial ART Regimen.

<p>HIV: human immunodeficiency virus, ART: antiretroviral therapy, ADI: AIDS defining illness.</p>a<p>Age at the start of ART.</p>b<p>Reported mode of HIV risk exposure was categorized injection drug users (IDU) and not IDU.</p>c<p>Pre-treatment CD4+ cell count and HIV RNA were defined as the value closest to the date of start of ART up to 6 months prior.</p>d<p>Initial ART regimen was classified as NNRTI-based or PI-based. Integrase inhibitor-based regimens were too few (N = 75) to draw consistent conclusions and were thus excluded.</p>e<p>ADI at the start of ART was defined as the presence of any CDC 1993 condition at six months prior to up to one month after start of ART.</p>f<p>Hepatitis B/C co-infection was defined as having chronic infection at the start of ART.</p>h<p>Significant cohort and ADI interaction term [aOR 2.02 (1.42, 2.86)].</p